article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.

article thumbnail

Medical Marijuana Offers Hope for Treatment of PTSD

FloridaMarijuana.net

According to a 2017 report published by the National Academies of Sciences , PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. Treatment usually aims at reducing reactions and to diminishing the acuity of the reactions. Get your Florida Medical Marijuana Card.

Treatment 182
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

1 in 5 Parkinson’s Patients Use Cannabis

CannaMD

Non-uses were also asked what factors might cause them to consider adding medical marijuana to their treatment regime. More than 80% of survey respondents indicated strong interest in learning more information about a clinical trial, and more than half were interested in enrolling in a clinical trial.

Patients 105
article thumbnail

Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It

The Cannigma

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. Still, research is ongoing.

article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] In 2017, FDA granted a request for Breakthrough Therapy designation for MDMA to treat PTSD. Defining Psychedelics.

article thumbnail

Harvard Law Review: Patents on Psychedelics: The Next Legal Battlefront of Drug Development

Cannabis Law Report

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. TIMES (Nov.

article thumbnail

Harvard Law School Announces the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics

Cannabis Law Report

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression.

Law 59